27072 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dr Reddy's gets USFDA nod for Ondansetron
Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from the US Food and Drug Administration (USFDA), as well as a 6-month marketing exclusivity.
Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from the US Food and Drug Administration (USFDA), as well as a 6-month marketing exclusivity.
The Hyderabad based pharma major announced that the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) for Ondansetron Hydrochloride Tablets in dosages of 4mg, 8mg, 16mg and 24mg.
Marketing exclusivity
As the first company to file an ANDA containing a paragraph IV certification for this product, the company has also been awarded a 180-day period of marketing exclusivity, a press release from the company said.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Motherson Sumi | Iran | Suzlon Energy | Reliance Power | Singapore Telecommunications | Sun Pharma | BSE Sensex | Tamil Nadu | Coal India IPO | State Bank of India 
The Hyderabad based pharma major announced that the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) for Ondansetron Hydrochloride Tablets in dosages of 4mg, 8mg, 16mg and 24mg. 
